JAZZ PHARMACEUTICALS INC Form 425 October 18, 2011

Filing under Rule 425 under the Securities Act of 1933 and deemed filed under Rule 14a-12 of the Securities Exchange Act of 1934

Filing by: Jazz Pharmaceuticals, Inc. Subject Company: Jazz Pharmaceuticals, Inc. SEC File No. of Jazz Pharmaceuticals, Inc.: 001-33500

The following is a slide presentation relating to the proposed transactions described therein that was made available beginning on October 18, 2011.

Bruce Cozadd Chairman and CEO October 18, 2011 Introduction to Jazz Pharmaceuticals

2

Forward-Looking Statements

This presentation contains forward-looking statements, including, but not limited to, statements related to the anticipated consummation of the business combination transaction between Jazz Pharmaceuticals and Azur Pharma and the timing and benefits thereof, the combined company s, and each respective company s, strategy, plans, objectives, expectations (financial

or

otherwise)
and
intentions,
future
financial
results
and
growth
potential
(including
Jazz
Pharmaceuticals
2011
Financial Guidance), anticipated product portfolio, development programs, intellectual property and tax position,
management structure, and other statements that are not historical facts. These forward-looking statements are based on
Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Actual results and the
timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks
and
uncertainties,
which
include,
without
limitation,
risks
related
to
Jazz
Pharmaceuticals
ability
to
complete
the
transaction
on the proposed terms and schedule; risks associated with business combination transactions, such as the risk that the
businesses will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than
expected; risks related to future opportunities and plans for the combined company, including uncertainty of the expected
financial performance and results of the combined company following completion of the proposed transaction; disruption

businesses will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; risks related to future opportunities and plans for the combined company, including uncertainty of the expected financial performance and results of the combined company following completion of the proposed transaction; disruption from the proposed transaction, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; the calculations of, and factors that may impact the calculations of, the acquisition price in connection with the proposed merger and the allocation of such acquisition price to the net assets acquired in accordance with applicable accounting rules and methodologies; and the possibility that if the combined company does not achieve the perceived benefits of the proposed transaction as rapidly or to the extent anticipated by financial analysts or investors, the market price of the combined company s shares could decline, as well as other risks related to Jazz Pharmaceuticals business,

including

Jazz

Pharmaceuticals

dependence

on

sales

Edgar 1 milg. 0, 122 1 1 // 11 www. 102 0 11 0 / 12 0 mil 120
of
Xyrem
$^{\circ}$
and its ability to increase sales of its Xyrem and
Luvox
CR
$^{\circ}$
products;
competition,
including
potential
generic
competition;
Jazz
Pharmaceuticals
dependence
on
single
source suppliers and manufacturers; the ability of Jazz Pharmaceuticals to protect its intellectual property and defend its
patents; regulatory obligations and oversight; Jazz Pharmaceuticals cash flow; and those risks detailed from time-to-time
under
the
caption
Risk
Factors
and
elsewhere
in
Jazz
Pharmaceuticals
SEC filings and reports, including in its Quarterly
Report on Form 10-Q for the quarter ended June 30, 2011. Jazz Pharmaceuticals undertakes no duty or obligation to
update
any
forward-looking
statements
contained
in
this
presentation
as
a
result
of
new
information,
future
events
or
changes in its expectations.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Additional Information In connection with the proposed

Edga: 1 milg. 0.122 1 1.7.1 m. (62 6 11 6 7 6 11 12 6
business
combination
transaction
described
in
this
presentation,
Jazz
Pharmaceuticals
and
Azur
Pharma
will
be
filing
documents
with
the
SEC,
including
the
filing
by
Jazz
Pharmaceuticals
of
a
preliminary
and and
definitive proxy statement/prospectus relating to the proposed transaction and the filing by Azur Pharma of a registration
statement on Form S-4 that will include the proxy statement/prospectus relating to the proposed transaction. After the
registration
statement
has
been
declared
effective
by
the
SEC,
a
definitive
proxy
statement/prospectus
will
be
mailed
to
Jazz Pharmaceuticals stockholders in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS
ARE

URGED
TO
READ
THE
REGISTRATION
STATEMENT
ON
FORM
S-4
AND THE RELATED PRELIMINARY AND
DEFINITIVE PROXY/PROSPECTUS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORT
INFORMATION ABOUT JAZZ PHARMACEUTICALS, AZUR PHARMA AND THE PROPOSED TRANSACTION. Invo
and security holders may obtain free copies of these documents (when they are available) and other related documents filed
with
the
SEC
at
the
SEC s
web
site
at
www.sec.gov,
by
directing
a
request
to Laws
Jazz Pharmaceuticals
Investor
Relations
department at Jazz Pharmaceuticals, Inc., Attention: Investor Relations, 3180 Porter Drive, Palo Alto, California 94304, or to
Jazz
Pharmaceuticals
Investor
Relations
department
at
650-496-2800
or
by
email
to
investorinfo@jazzpharma.com.
Investors and security holders may obtain free copies of the documents filed with the SEC on Jazz Pharmaceuticals
website
at
www.jazzpharmaceuticals.com
under

the
heading
Investors
and
then
under
the
heading
SEC
Filings.
Jazz
Pharmaceuticals and its directors and executive officers and Azur Pharma and its directors and executive officers may be
deemed
participants
in
the
solicitation
of
proxies
from
the
stockholders
of
Jazz
Pharmaceuticals in connection with the
proposed transaction. Information regarding the special interests of these directors and executive officers in the proposed
transaction will be included in the proxy statement/prospectus described above. Additional information regarding the
directors
and
executive
officers
of T
Jazz Planting to the second se
Pharmaceuticals
is .
also
included .
in .
Jazz
Pharmaceuticals
proxy
statement
for
its
2011 Annual Meeting of Stockholders, which was filed with the SEC on April 12, 2011. These documents are available free
of charge
at
the and the second seco
SEC s
web

site
at
www.sec.gov
and
from
Investor
Relations

at

Jazz

Pharmaceuticals

aç

described

above.

This communication does not constitute an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

For full prescribing information refer to product websites.

Additional Information and Where to Find It

Building Shareholder Value by Focusing on Patient Needs Jazz Pharmaceuticals mission is to improve patients lives by identifying, developing and commercializing valuable pharmaceutical products in focused therapeutic areas

5
Pursue lower risk
development of
specialty products
Invest percentage
of sales longer-term
Strategy to Build Shareholder Value

Grow Xyrem sales in current indications
Increased focus on achieving full potential
Acquire additional
marketed or close to approval products
Leverage our expertise and infrastructure
2
Maintain entrepreneurial, ownership culture at the company
Make disciplined resource allocation decisions
1
3
4

Current Business and Financial Overview

\$39

\$54 \$97

\$215-225

2010

2009

2008

2007 2011G

```
$143
Xyrem -
Strong Sales Growth
2011 Guidance $215M-$225M
8\%
7
$0
$25
$50
$75
$100
$175
$200
$125
$150
$225
$250
1.
Based on guidance provided on July 28, 2011. The company is not updating the prior guidance and actual results may differ.
1
```

Xyrem is a Standard of Care in Narcolepsy

Only FDA-approved product for both cataplexy and excessive daytime sleepiness in patients with narcolepsy

Marketed in U.S. since 2002

Marketed in major European countries by UCB and in Canada by Valeant

Currently marketed in U.S. by 110-person specialty sales force

Approximately 8,700 patients on therapy, usually in conjunction with stimulant therapy

Distributed under proprietary Xyrem Success

Program

®

8

```
The Burden of Narcolepsy
Affects 1 in 2000 in US
multiple sclerosis and Parkinson's disease
> cystic fibrosis
Although narcolepsy is thought to affect between
125,000 and 200,000 Americans, only about
50,000 are diagnosed
4
Key symptoms can be debilitating
Cataplexy occurs in 60%-100% of patients
100% experience excessive daytime sleepiness
9
1.
National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/narcolepsy/detail_narcolepsy.htm
Narcolepsy Sleep Foundation. www.sleepfoundation.org/article/sleep-related-problems/narcolepsy-and-sleep. Accessed March
3.
```

Zemanick et al. J Cyst Fibros. 2010;9:1-16.

4

American Sleep Association. http://www.sleepassociation.org/index.php?p=aboutnarcolepsy. Accessed March 17, 2011.

```
-40
```

Λ

Xyrem has Demonstrated Effect on Two Key Symptoms of Narcolepsy

⁻³⁰

⁻²⁰

⁻¹⁰

XYREM 6 g/night

study

```
(n=58)
XYREM
9 g/night
(n=47)
Placebo
(n=59)
 16%
 37%
 3%
Improvement in Epworth
Sleepiness Scale
Week 2
Week 4
Baseline
Reduction in Weekly
Cataplexy Attacks
*p<0.001 vs placebo
*p<0.05 vs placebo
+p<0.005 vs placebo
-28%
-49%*
-69%+
10
-80
-60
-40
-20
0
Placebo (n=33)
XYREM 6 g/night (n=31)
XYREM 9 g/night (n=33)
Trial 3: From a 8-week, multicenter, randomized, double-blind, placebo controlled, parallel-arm trial of narcolepsy patients (N
Trial 1: From a 4-week, double-blind, placebo-controlled trial of narcolepsy patients (N=136) with moderate to severe cataples
sodium oxybate with placebo for the treatment of narcolepsy. Patients continued to receive stable stimulant therapy throughout
1.
2.
randomization,
and
stimulants
were
continued
throughout
the
```

at

stable

doses.

In

XYREM

clinical

trials,

80%

of

patients

maintained

concomitant

stimulant

use.

XYREM

International

Study

Group.

J

Clin

Sleep

Med.

2005;1:391.


```
Most Common Adverse Events in
Controlled Studies of Xyrem
Adverse Event
% of Patients (N=655)
Placebo
Xyrem
Nausea
4
19
Dizziness
4
18
Headache
15
18
Vomiting
8
Somnolence
4
Urinary incontinence
4
<1
Nasopharyngitis
5
6
Label includes boxed warning that sodium oxybate is a central nervous system
depressant with abuse potential and should not be used with alcohol or other
CNS depressants. See complete boxed warning at end of presentation.
11
```

1. Occurring in 5% of XYREM patients and more frequently than with placebo. 2. Data on file, Jazz Pharmaceuticals, Inc.

Strong Sodium Oxybate Patent Coverage
* Listed in FDA Orange Book
12
Number
Issue Date
Expiration Date
Distribution system patent*

7,765,106 7/27/2010 6/16/2024 Distribution system patent* 7,765,107 7/27/2010 6/16/2024 Distribution system patent 7,797,171 9/14/2010 6/16/2024 Distribution system patent* 7,668,730 2/23/2010 6/16/2024 Distribution system patent* 7,895,059 2/23/2011 12/17/2022 Formulation patent* 6,780,889 8/24/1999 7/4/2020 Formulation patent* 7,262,219 8/28/2007 7/4/2020 Process patent 6,472,431 10/29/1999 12/22/2019 Method of use patent* 7,851,506

12/14/2010 12/22/2019



Overview of Manufacturing and Distribution

DEA drug quota needed to manufacture controlled Schedule I API

Exclusive relationships with API supplier and finished goods manufacturer

Unique proprietary distribution system uses exclusive single pharmacy

Risk management program and unique product attributes require high touch commercial capabilities

13



Current Xyrem Patient Coverage Distribution*

Approximately 90% of insured patients have access

Relatively low rates of required prior authorizations

Low monthly out-of-pocket (OOP) expenses Over 70% of patients have monthly OOP of \$50 79% 8% 3% 1% 9% * Company data and MediMedia Formulary Compass July 2011. Commercial

Medicaid Medicare Part D Patient Asst Program Cash 14

15

New narcolepsy physician targets

Xyrem Success Program education

Patient services

-

Nursing program

-

Xyrem Patient Connection

-

Patient assistance programs
Increased Marketing Investment
Xyrem Growth Initiatives
Improve Market Penetration Over Time
Current Patients = ~ 8,700
Approximately 17% of 50K Diagnosed Narcolepsy Patients

Important Treatment Option for OCD Indicated for obsessive compulsive disorder (OCD) **OCD** affects 2.2 million Americans 1,2 Often underdiagnosed 3,4 Difficult to differentiate from comorbidities Only 43% of adults newly diagnosed with OCD received adequate treatment in the year after their first visit for **OCD**

Label includes boxed warning regarding suicidality and antidepressant drugs.

See complete boxed warning at end of presentation.

- 1. National Institute of Mental Health. http://www.nimh.nih.gov/health/publications/the-numbers-count-mental-disorders-in-ar
- 3. Fireman B, et al. Am J Psychiatry. 2001;158:1904-1910. 4. Grabill K et al.. Assessment of obsessive-compulsive disorder: a 1999:600-610. 6. Koran LM, et al. Am J Health Syst Pharm. 2000;57:1972-1978.

Luvox CR Continued Sales Growth 2011 Guidance \$32M-\$35M 1 \$30 \$6 \$32-35

2009 2008 2011G 17 \$0 \$5 \$10 \$15 \$20 \$25 2010 \$18 \$35 \$40 \$27 1.

Based on guidance provided on July 28, 2011. The company is not updating the prior guidance and actual results may differ.

Includes \$2.0 million of revenue recorded as a result of a change in the timing of when Luvox CR revenue is recognized. The creturns.

2

18

2011 Guidance Reflects High Operating Leverage

1.

Based on guidance provided on July 28, 2011. The company is not updating the prior guidance and actual results may differ.

2.

Adjusted

net income and adjusted **EPS** are non-GAAP financial measures that exclude certain items from **GAAP** net income and **GAAP** EPS. A reconciliation of adjusted net income GAAP net income and the related per share amounts is in a table included with this presentation. 2010-A 2011-G **Total Product Sales** \$170M \$247 260M Xyrem \$143M \$215 225M Luvox CR \$27M \$32 35M SG&A and R&D Combined \$95M \$105 110M

GAAP Net Income

\$33M \$123 131M Adjusted Net Income 2 \$61M \$145 153M GAAP EPS \$0.83 \$2.68 -\$2.79 Adjusted EPS 2 \$1.55

\$3.15 \$3.25

19 Investment Rationale

High sales and earnings growth rates

High margins and high operating leverage

Significant potential to increase Xyrem sales

Strong Xyrem exclusivity position including patents extending to 2024

Potential to leverage existing commercial capabilities with new products

Disciplined approach to resource allocation

Strategic Transaction with Azur Pharma

21 Strategic Benefits

Diversified portfolio of CNS and women s health products

Increased scale and platform

for growth

Resources to invest in future pipeline and strong franchise management opportunities

Stronger, enhanced management team Projected Financial Benefits

Accretive transaction

Revenues >\$475M and cash flow >\$200M in first 12 months

~\$250M cash at closing

Strong balance sheet with no debt

1

Accretion for Jazz Pharmaceuticals shareholders is on a fully-taxed adjusted EPS basis. Adjusted EPS is a non-GAAP financia

Pro forma estimate as of Jan 1, 2012.

Compelling Strategic and Financial Benefits

Jazz

Pharmaceuticals plc

Ireland

22 Jazz Pharmaceuticals plc 12 products currently marketed in US >\$475 million in revenues in first 12 months >\$200 million in cash generated in first 12 months Jazz Pharmaceuticals: slightly under 80%; Azur Pharma: slightly over 20% Combined capitalization approximately 60M shares fully diluted at closing

Jazz

Pharmaceuticals

board
represented
funds
entered
into
voting
agreements (~43% of shares)

99%

of

Azur

shareholders entered into agreement to take necessary actions

Current directors of Jazz Pharmaceuticals

Seamus Mulligan (Chairman and CEO, Azur Pharma)

Portfolio & Financial

Projections

Ownership in

Combined Company

Shareholder Votes

Board of Directors

Management

Bruce Cozadd, Chairman and CEO

Kate Falberg, CFO

Seamus Mulligan, Chief Business Officer, International Business Development

Azur executives join JPI executives in leadership roles

Anticipated Closing: 1Q12

23

Azur Pharma

Compelling Fit With Jazz Pharmaceuticals

\$0

\$20

\$40

\$60

\$80

\$100

2006

2007

2008

2009

2010

CNS

Women s Health

Net Sales

(Millions)

Strong commercial focus and expertise in CNS and women s health

Key products present new growth opportunities

Lower risk pipeline of line extensions for clozapine franchise and LCM programs for key women s health brands

24
2011 Estimated Revenues
Stand Alone Jazz Pharmaceuticals, Inc.
Pro forma Jazz Pharmaceuticals plc
A Growing, Diversified Product Portfolio
Luvox CR
13%

Xyrem 87%

Xyrem 63%

Luvox CR

9%

Prialt 6%

Women s

Health 10%

Other CNS

1%

FazaClo LD

8%

FazaClo HD

3%

25

Sourcing of new products for all markets

Potential expansion into Europe Benefits of New Corporate Structure Access to international capital markets and business development

opportunities

Sales, marketing, and clinical/medical science liaison organizations

Multi-product supply chain management

BD executives with demonstrated success Enhanced management capabilities

Enhanced ability to attract and retain key talent Additional locations (Philadelphia, Dublin) Parent company in Ireland expected to license, develop and acquire existing and new products Next Steps
File preliminary proxy
statement and S-4
Expected to
close 1Q12
Transaction is
subject to customary
closing conditions
and regulatory
approvals, including:

SEC effectiveness of S-4

Jazz Pharmaceuticals, Inc. stockholder approval

Azur approval of other necessary actions

Antitrust clearance

Transaction will be taxable to Jazz Pharmaceuticals, Inc. stockholders

Jazz Pharmaceuticals plc shares to be traded on Nasdaq

27 Strategic Benefits

Diversified portfolio of CNS and women s health products

Increased scale and platform for growth

Resources to invest in future pipeline and strong franchise management opportunities

Stronger, enhanced management team Projected Financial Benefits

Accretive transaction

Revenues >\$475M and cash flow >\$200M in first 12 months

~\$250M cash at closing

Strong balance sheet

with no debt

1

Accretion for Jazz Pharmaceuticals shareholders is on a fully-taxed adjusted EPS basis. Adjusted EPS is a non-GAAP financial

Pro forma estimate as of Jan 1, 2012.

Compelling Strategic and Financial Benefits

Jazz

Pharmaceuticals plc

Ireland

1

2

29 FY 2011G FY 2010

Reconciliation of GAAP Net Income and EPS to Adjusted

Net Income and EPS in Financial Results and Guidance

(In millions, except per share amounts)

GAAP net income

Add:

Intangible asset amortization

Stock-based compensation expense

Non-cash interest expense

Loss on extinguishment of debt

Deduct:

Contract revenues

GAAP net income per diluted share (EPS)

Adjusted net income per diluted share (EPS)

Shares used in computing GAAP and adjusted net

income per diluted share amounts

Adjusted net income

Luvox CR revenue recognition timing change

(1)

\$123-131

7

```
14
2
$145-153
$2.68-2.79
$3.15-3.25
46-47
(1)
$33
8
8
2
$61
$0.83
$1.55
39
12
(1)
1.
Based on guidance provided on July 28, 2011. The company is not
updating the prior guidance and actual results may differ.
1
```

30 Xyrem (sodium oxybate) Boxed Warning Sodium oxybate is

Edgar 1 milg. 07.22 1 17.4 mily. 626 116.426 mily. 126
GHB,
a
known
drug
of State of
abuse.
Abuse
has
been
associated
with
some
important
central
nervous
system
(CNS) adverse events (including death). Even at recommended doses, use has been associated with confusion, depression
and other neuropsychiatric
events.
Reports
of
respiratory
depression
occurred
in
clinical
trials.
Almost
all
of
the
patients
who
received sodium oxybate during clinical trials were receiving CNS stimulants.
Important CNS adverse events associated with abuse of GHB include seizure, respiratory depression and profound decreases
in level
of
consciousness,
with
instances
of
coma
and
death.
For
events
that
occurred
outside
of


clinical trials, in people taking GHB for recreational purposes, the circumstances surrounding the events are often unclear (e.g., dose of **GHB** taken, the nature and amount of alcohol or any concomitant drugs). Xyrem is available through the Xyrem Success Program, using a centralized pharmacy 1-866-XYREM88 (1-866-997-3688). The Success Program provides educational materials to the prescriber and the patient explaining the risks

and

proper
use of
sodium oxybate,
and
the
required
prescription
form.
Once
it
is
documented
that
the
patient
has
read
and/or
understood
the
materials,
the
drug
will
be
shipped
to the
patient. The
Xyrem Success
Program
also recommends
patient follow up
follow-up every 3
months. Physicians are expected to report all serious adverse events to the manufacturer. (See WARNINGS). XYREM (sodium oxybate) PI
!WARNING:
Central
nervous
system
depressant with
abuse
potential. Should
not

be used with alcohol or other CNS depressants.

Luvox CR
(fluvoxamine maleate)
Boxed Warning
LUVOX CR (fluvoxamine maleate) PI
Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking
and behavior (suicidality) in children, adolescents, and young adults in short-term



Clinical Worsening

and

Suicide

Risk,

PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use.)